{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T11:31:01Z","timestamp":1769167861885,"version":"3.49.0"},"reference-count":54,"publisher":"BMJ","issue":"3","funder":[{"name":"Key Research and Development Plan of Zhenjiang"},{"DOI":"10.13039\/501100012246","name":"Priority Academic Program Development of Jiangsu Higher Education Institutions","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012246","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2019,2,27]]},"published-print":{"date-parts":[[2019,3]]},"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Tuberculosis (TB) continues to be an important public health problem throughout much of the world. Drug treatment is the only effective treatment method, but adverse drug events (ADEs) and adverse drug reactions (ADRs) can affect medication adherence. As the number of drug-resistant TB patients and the number of anti-TB drugs have increased, it is necessary to explore the risk factors for ADEs\/ADRs to reduce their occurrence. This study aims to build a home-based anti-TB treatment cohort and to recognise the incidences, prognosis and risk factors of anti-TB drug-induced ADEs\/ADRs in real-world experiences.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods and analysis<\/jats:title><jats:p>This study is a multicentre, prospective observational cohort study. The study population will consist of 3200 newly diagnosed TB patients between January 2019 and December 2020. After initiating the anti-TB treatment, all patients will be followed up until finishing treatment unless they withdraw, and we will record personal drug use and signs and\/or symptoms of discomfort. Patients will receive scheduled laboratory tests in designated hospitals every 2\u2009weeks during the first 2\u2009months, and the residual blood sample after conducting the laboratory tests will be preserved. The ADEs\/ADRs will be placed into eight categories: liver dysfunction, gastrointestinal reactions, drug allergy, arthralgia or muscle pain, nervous system disorders, haematological system disorders, renal impairment and others.<\/jats:p><\/jats:sec><jats:sec><jats:title>Ethics and dissemination<\/jats:title><jats:p>This study protocol has been approved by the ethics committees of Nanjing Medical University. All patients will give written informed consent before enrollment. The findings of the study will be published in peer-reviewed journals and will be presented at national and international conferences.<\/jats:p><\/jats:sec>","DOI":"10.1136\/bmjopen-2018-027321","type":"journal-article","created":{"date-parts":[[2019,3,30]],"date-time":"2019-03-30T14:56:13Z","timestamp":1553957773000},"page":"e027321","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":15,"title":["Home-based Anti-Tuberculosis Treatment Adverse Reactions (HATTAR) study: a protocol for a prospective observational study"],"prefix":"10.1136","volume":"9","author":[{"given":"Miaomiao","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongqiu","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lihuan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaomin","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongbo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bilin","family":"Tao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenpei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Honggang","family":"Yi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5879-8594","authenticated-orcid":false,"given":"Shaowen","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2019,3,30]]},"reference":[{"key":"2024052011580356000_9.3.e027321.1","unstructured":"WHO. Global tuberculosis report 2018. Geneva: World Health Organization, 2018."},{"key":"2024052011580356000_9.3.e027321.2","unstructured":"WHO. Global tuberculosis control: surveillance, planning and Financing. Geneva: World Health Organization, 2005."},{"key":"2024052011580356000_9.3.e027321.3","first-page":"197","article-title":"Factors associated with tuberculosis treatment outcomes among tuberculosis patients attending tuberculosis treatment centres in 2016-2017 in Mogadishu, Somalia","volume":"28","author":"Ali","year":"2017","journal-title":"Pan Afr Med J"},{"key":"2024052011580356000_9.3.e027321.4","first-page":"21","article-title":"Adverse events to first line anti-tuberculosis drugs in patients co-infected with HIV and tuberculosis","volume":"14","author":"Michael","year":"2016","journal-title":"Ann Ib Postgrad Med"},{"key":"2024052011580356000_9.3.e027321.5","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-140-10-200405180-00017"},{"key":"2024052011580356000_9.3.e027321.6","doi-asserted-by":"crossref","first-page":"564","DOI":"10.4103\/0972-5229.164819","article-title":"System of adverse drug reactions reporting: What, where, how, and whom to report?","volume":"19","author":"Kalaiselvan","year":"2015","journal-title":"Indian J Crit Care Med"},{"key":"2024052011580356000_9.3.e027321.7","first-page":"144","article-title":"Incidence and risk factors of major toxicity associated to first-line antituberculosis drugs for latent and active tuberculosis during a period of 10 years","volume":"21","author":"Castro","year":"2015","journal-title":"Rev Port Pneumol"},{"key":"2024052011580356000_9.3.e027321.8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0065037","article-title":"Adverse reactions due to directly observed treatment strategy therapy in Chinese tuberculosis patients: a prospective study","volume":"8","author":"Lv","year":"2013","journal-title":"PLoS One"},{"key":"2024052011580356000_9.3.e027321.9","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.12659\/MSM.904682","article-title":"Adverse events associated with treatment of multidrug-resistant tuberculosis in China: an ambispective cohort study","volume":"23","author":"Zhang","year":"2017","journal-title":"Med Sci Monit"},{"key":"2024052011580356000_9.3.e027321.10","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1186\/s12879-016-1933-0","article-title":"Severe adverse events during second-line tuberculosis treatment in the context of high HIV Co-infection in South Africa: a retrospective cohort study","volume":"16","author":"Schnippel","year":"2016","journal-title":"BMC Infect Dis"},{"key":"2024052011580356000_9.3.e027321.11","first-page":"2234","article-title":"A cross-sectional and follow-up study of leukopenia in tuberculosis patients: prevalence, risk factors and impact of anti-tuberculosis treatment","volume":"7","author":"Lin","year":"2015","journal-title":"J Thorac Dis"},{"key":"2024052011580356000_9.3.e027321.12","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1016\/j.lpm.2017.01.016","article-title":"The challenge of the new tuberculosis drugs","volume":"46","author":"Tiberi","year":"2017","journal-title":"La Presse M\u00e9dicale"},{"key":"2024052011580356000_9.3.e027321.13","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.ijtb.2017.03.002","article-title":"Drug development against tuberculosis: Past, present and future","volume":"64","author":"Vasava","year":"2017","journal-title":"Indian J Tuberc"},{"key":"2024052011580356000_9.3.e027321.14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2017\/3974651","article-title":"Tuberculosis Treatment Outcomes and Factors Associated with Each of Them in a Cohort Followed Up between 2010 and 2014","volume":"2017","author":"Cardoso","year":"2017","journal-title":"Biomed Res Int"},{"key":"2024052011580356000_9.3.e027321.15","doi-asserted-by":"crossref","first-page":"621","DOI":"10.5588\/ijtld.14.0996","article-title":"Adverse drug reactions in tuberculosis patients: consequences for TB control","volume":"19","author":"Naik","year":"2015","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024052011580356000_9.3.e027321.16","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.14.0369"},{"key":"2024052011580356000_9.3.e027321.17","first-page":"Lc05","article-title":"Home based care as an approach to improve the efficiency of treatment for MDR tuberculosis: a Quasi-Experimental Pilot Study","volume":"11","author":"Taneja","year":"2017","journal-title":"J Clin Diagn Res"},{"key":"2024052011580356000_9.3.e027321.18","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1186\/1471-2458-10-267","article-title":"Design of the anti-tuberculosis drugs induced adverse reactions in China National Tuberculosis Prevention and Control Scheme Study (ADACS)","volume":"10","author":"Xia","year":"2010","journal-title":"BMC Public Health"},{"key":"2024052011580356000_9.3.e027321.19","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/j.1365-2710.2012.01334.x","article-title":"CYP2E1, GSTM1 and GSTT1 genetic polymorphisms and susceptibility to antituberculosis drug-induced hepatotoxicity: a nested case-control study","volume":"37","author":"Tang","year":"2012","journal-title":"J Clin Pharm Ther"},{"key":"2024052011580356000_9.3.e027321.20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0021836","article-title":"Incidence, clinical features and impact on anti-tuberculosis treatment of anti-tuberculosis drug induced liver injury (ATLI) in China","volume":"6","author":"Shang","year":"2011","journal-title":"PLoS One"},{"key":"2024052011580356000_9.3.e027321.21","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/1440-1681.12074","article-title":"Lack of association between genetic polymorphisms of CYP3A4, CYP2C9 and CYP2C19 and antituberculosis drug-induced liver injury in a community-based Chinese population","volume":"40","author":"Tang","year":"2013","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"2024052011580356000_9.3.e027321.22","doi-asserted-by":"crossref","first-page":"812","DOI":"10.5588\/ijtld.15.0450","article-title":"CYP7A1, BAAT and UGT1A1 polymorphisms and susceptibility to anti-tuberculosis drug-induced hepatotoxicity","volume":"20","author":"Chen","year":"2016","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024052011580356000_9.3.e027321.23","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/jgh.12717","article-title":"Preventive use of hepatoprotectors yields limited efficacy on the liver toxicity of anti-tuberculosis agents in a large cohort of Chinese patients","volume":"30","author":"Wu","year":"2015","journal-title":"J Gastroenterol Hepatol"},{"key":"2024052011580356000_9.3.e027321.24","doi-asserted-by":"publisher","DOI":"10.1002\/wsbm.1323"},{"issue":"Suppl 1","key":"2024052011580356000_9.3.e027321.25","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1007\/s40264-014-0183-6","article-title":"Liver safety assessment: required data elements and best practices for data collection and standardization in clinical trials","volume":"37","author":"Avigan","year":"2014","journal-title":"Drug Saf"},{"key":"2024052011580356000_9.3.e027321.26","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jiph.2017.07.014","article-title":"Tuberculosis controlling, from China\u2019s perspective","volume":"11","author":"Wu","year":"2018","journal-title":"J Infect Public Health"},{"key":"2024052011580356000_9.3.e027321.27","unstructured":"WHO. Guidelines for treatment of drug-susceptible tuberculosis and patient care, 2017 update 2017."},{"key":"2024052011580356000_9.3.e027321.28","unstructured":"WHO. WHO treatment guidelines for drug-resistant tuberculosis, 2016 update, 2016."},{"key":"2024052011580356000_9.3.e027321.29","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3390\/ijerph13010086","article-title":"Adverse events in treating smear-positive tuberculosis patients in China","volume":"13","author":"Zhang","year":"2015","journal-title":"Int J Environ Res Public Health"},{"key":"2024052011580356000_9.3.e027321.30","unstructured":"WHO. The use of the WHO-UMC system for standardized case causality assessment. Uppsala: The Uppsala Monitoring, 2005."},{"key":"2024052011580356000_9.3.e027321.31","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.58"},{"key":"2024052011580356000_9.3.e027321.32","doi-asserted-by":"publisher","DOI":"10.1016\/0168-8278(90)90124-A"},{"key":"2024052011580356000_9.3.e027321.33","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2007.05207.x"},{"key":"2024052011580356000_9.3.e027321.34","unstructured":"Wj G , Jm M . QUANTO 1.1: a computer program for power and sample size calculations for genetic-epidemiology studies. 2006. http:\/\/biostats.usc.edu\/software"},{"key":"2024052011580356000_9.3.e027321.35","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62639-2"},{"key":"2024052011580356000_9.3.e027321.36","doi-asserted-by":"crossref","first-page":"299","DOI":"10.5588\/pha.17.0056","article-title":"Risk factors for unfavourable treatment outcome among new smear-positive pulmonary tuberculosis cases in China","volume":"7","author":"Lin","year":"2017","journal-title":"Public Health Action"},{"key":"2024052011580356000_9.3.e027321.37","doi-asserted-by":"crossref","first-page":"280","DOI":"10.5455\/njppp.2015.5.2502201543","article-title":"Evaluation of knowledge and perception toward adverse drug reactions among patients visiting tertiary-care teaching hospital","volume":"5","author":"Joshi","year":"2015","journal-title":"Natl J Physiol Pharm Pharmacol"},{"key":"2024052011580356000_9.3.e027321.38","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/bcp.13098","article-title":"The value of patient reporting to the pharmacovigilance system: a systematic review","volume":"83","author":"In\u00e1cio","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"2024052011580356000_9.3.e027321.39","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-013-0021-2"},{"key":"2024052011580356000_9.3.e027321.40","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s40264-014-0162-y","article-title":"Adverse drug reaction reporting by patients: an overview of fifty countries","volume":"37","author":"Margraff","year":"2014","journal-title":"Drug Saf"},{"key":"2024052011580356000_9.3.e027321.41","doi-asserted-by":"crossref","first-page":"193","DOI":"10.5455\/aim.2016.24.193-196","article-title":"Mobile Phone Based System Opportunities to Home-based Managing of Chemotherapy Side Effects","volume":"24","author":"Davoodi","year":"2016","journal-title":"Acta Inform Med"},{"key":"2024052011580356000_9.3.e027321.42","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx317"},{"key":"2024052011580356000_9.3.e027321.43","doi-asserted-by":"crossref","unstructured":"Holch P , Pini S , Henry AM , et al . eRAPID electronic patient self-Reporting of Adverse-events: Patient Information and aDvice: a pilot study protocol in pelvic radiotherapy. Pilot Feasibility Stud 2018;4.doi:10.1186\/s40814-018-0304-6","DOI":"10.1186\/s40814-018-0304-6"},{"key":"2024052011580356000_9.3.e027321.44","doi-asserted-by":"publisher","DOI":"10.1590\/S1806-37132010000500016"},{"key":"2024052011580356000_9.3.e027321.45","unstructured":"Srivastava Ak . Pharmacology: A Book Of Achieving Knowledge For Drugs. New Delhi: Educreation Publishing, 2017."},{"key":"2024052011580356000_9.3.e027321.46","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2006.04197.x"},{"key":"2024052011580356000_9.3.e027321.47","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1007\/s40261-017-0572-6","article-title":"Genetic polymorphisms of SLCO1B1, CYP2E1 and UGT1A1 and susceptibility to anti-tuberculosis drug-induced hepatotoxicity: a Chinese population-based prospective case-control study","volume":"37","author":"Sun","year":"2017","journal-title":"Clin Drug Investig"},{"key":"2024052011580356000_9.3.e027321.48","doi-asserted-by":"publisher","DOI":"10.5808\/GI.2012.10.2.117"},{"key":"2024052011580356000_9.3.e027321.49","doi-asserted-by":"crossref","unstructured":"Yew WW , Chang KC , Chan DP . Oxidative stress and first-line antituberculosis drug-induced hepatotoxicity. Antimicrob Agents Chemother 2018;62.doi:10.1128\/AAC.02637-17","DOI":"10.1128\/AAC.01633-18"},{"key":"2024052011580356000_9.3.e027321.50","doi-asserted-by":"publisher","DOI":"10.3109\/01480545.2015.1092039"},{"key":"2024052011580356000_9.3.e027321.51","first-page":"97","article-title":"Induction of oxidative stress in antitubercular drug-induced hepatotoxicity","volume":"20","author":"Chowdhury","year":"2001","journal-title":"Indian J Gastroenterol"},{"key":"2024052011580356000_9.3.e027321.52","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/(SICI)1099-1220(199609)2:3<197::AID-IJPG37>3.0.CO;2-6","article-title":"The floating population: an informal process of urbanisation in China","volume":"2","author":"Chang","year":"1996","journal-title":"Int J Popul Geogr"},{"key":"2024052011580356000_9.3.e027321.53","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1590\/S0036-46652013000500013","article-title":"Males, ages \u2265 45 years, businessperson, floating population, and rural residents may be considered high-risk groups for tuberculosis infection in Guangzhou, China: a review of 136,394 tb confirmed cases","volume":"55","author":"Li","year":"2013","journal-title":"Rev Inst Med Trop Sao Paulo"},{"key":"2024052011580356000_9.3.e027321.54","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s10096-010-1125-6","article-title":"Contribution of rural-to-urban migration in the prevalence of drug resistant tuberculosis in China","volume":"30","author":"Wang","year":"2011","journal-title":"Eur J Clin Microbiol Infect Dis"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2018-027321","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T19:15:49Z","timestamp":1716232549000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2018-027321"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":54,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,3,30]]},"published-print":{"date-parts":[[2019,3]]}},"alternative-id":["10.1136\/bmjopen-2018-027321"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2018-027321","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3]]}}}